Pronto Diagnostics

Company Overview

Snapshot

Founded in July 1993 by Nir Navot, Pronto Diagnostics operates with 11–50 employees. The company was acquired by Novolog Group in October 2022.

Business overview

Pronto Diagnostics develops, produces, and distributes genetic testing kits designed for the rapid and accurate detection of polymorphisms in DNA sequences linked to genetic diseases and disease predisposition. The company's kits, which test for over 35 different DNA variants, are suitable for both small-scale and large-scale clinical genetic analysis, meeting international quality standards and holding the European CE mark. Pronto Diagnostics serves the Health Tech & Life Sciences sector, providing solutions for clinical diagnosis and genetic analysis.

Strategic signal

In October 2022, Pronto Diagnostics was acquired by Novolog Group, a move that signals a strategic consolidation within the health tech and life sciences sector. This acquisition highlights the value placed on advanced genetic diagnostic capabilities and suggests a potential for expanded market reach and integration of Pronto Diagnostics' technology within a larger healthcare framework.

Company Intelligence Q&A

What is Pronto Diagnostics' primary focus?

Pronto Diagnostics develops, produces, and distributes genetic testing kits for the clinical diagnosis of genetic diseases and predisposition to disease.

When was Pronto Diagnostics founded?

Pronto Diagnostics was founded in July 1993.

Who founded Pronto Diagnostics?

Nir Navot is the founder of Pronto Diagnostics.

What was a significant corporate milestone for Pronto Diagnostics?

In October 2022, Novolog Group acquired 75% of Pronto Diagnostics for approximately ILS 11 million, marking a significant corporate milestone for the company.

What type of products does Pronto Diagnostics offer?

Pronto Diagnostics offers genetic testing kits, including products like ProntoLab and PGDlight, which are designed for detecting DNA variants associated with genetic conditions.